Eastwood Bio-Medical Canada Inc. Stock price

Equities

EBM

CA27783W1059

Pharmaceuticals

Market Closed - Toronto S.E. 02:35:43 2024-03-27 pm EDT 5-day change 1st Jan Change
0.8 CAD 0.00% Intraday chart for Eastwood Bio-Medical Canada Inc. +56.86% +45.45%
Sales 2022 1.3M 959K Sales 2023 868K 640K Capitalization 55.11M 40.66M
Net income 2022 - 0 Net income 2023 - 0 EV / Sales 2022 66.3 x
Net Debt 2022 22.41K 16.53K Net Debt 2023 43.52K 32.1K EV / Sales 2023 63.5 x
P/E ratio 2022
-575 x
P/E ratio 2023
-101 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 30.45%
More Fundamentals * Assessed data
Dynamic Chart
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2023 CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023 CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023 CI
Eastwood Bio-Medical Canada Inc. Auditor Raises 'Going Concern' Doubt CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2022 CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022 CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022 CI
Eastwood Bio-Medical Canada Inc.(TSXV:EBM) dropped from S&P/TSX Venture Composite Index CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2022 CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2021 CI
Eastwood Bio-Medical Canada Inc. Auditor Raises 'Going Concern' Doubt CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter Ended July 31, 2021 CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter Ended April 30, 2021 CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2020 CI
More news
1 week+56.86%
Current month+25.00%
1 month+25.00%
3 months+45.45%
6 months+14.29%
Current year+45.45%
More quotes
1 week
0.80
Extreme 0.8
0.80
1 month
0.40
Extreme 0.4
0.81
Current year
0.40
Extreme 0.4
0.88
1 year
0.40
Extreme 0.4
1.15
3 years
0.40
Extreme 0.4
2.72
5 years
0.00
Extreme 0
4.85
10 years
0.00
Extreme 0
8.49
More quotes
Managers TitleAgeSince
Chief Executive Officer - 20-09-03
Director of Finance/CFO 41 12-04-30
Director/Board Member 63 19-07-17
Members of the board TitleAgeSince
Director/Board Member 77 13-07-07
Director/Board Member 63 19-07-17
Director of Finance/CFO 41 12-04-30
More insiders
Date Price Change Volume
24-03-27 0.8 0.00% 4,000
24-03-26 0.8 +14.29% 500

Delayed Quote Toronto S.E., March 27, 2024 at 02:35 pm EDT

More quotes
Eastwood Bio-Medical Canada Inc. is engaged in marketing and distributing natural health products in North America. It is a licensed distributor of the Eleotin line of products, which include formulations based on natural ingredients that are presented in tea or capsule forms. The Eleotin products include natural remedies for certain metabolic disorders such as blood glucose disorders, hypertension and obesity, and can be used as a dietary supplement. Its licensed products include Eleotin A 700, which is a treatment for spleen deficiency, lack of appetite and fatigue; Eleotin AL88, a laxative; Eleotin Cal20, for bone and teeth maintenance; Eleotin V3D, for the development and maintenance of bones, teeth and good health; Eleotin G2000, for cardiovascular health; Eleotin H55, for sedative and tension relief, and Eleotin Zn330, for the tissue formation and metabolism. In addition, it offers Eleotin Bentley to promote healthy glucose levels and Eleotin LBM for hypertension relief.
More about the company
  1. Stock
  2. Equities
  3. Stock Eastwood Bio-Medical Canada Inc. - Toronto S.E.